Seattle Genetics, Takeda deal

Seattle Genetics will receive a $5 million milestone payment from Takeda under a 2009 deal to co-develop Adcetris brentuximab vedotin. The payment was triggered by annual Adcetris net sales exceeding $100 million in Takeda territories. Last month, Seattle Genetics said Japan approved the drug for CD30-positive relapsed or refractory Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL). Adcetris is now approved in 39 countries (see BioCentury, Dec. 21, 2009 & Jan. 20, 2014). ...